Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Orbsen Therapeutics Limited is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are assigned to 2 distinct examiners, ensuring that each matter is under independent review. The workload is also divided between 2 distinct art units, which reflects a breadth of technical subject matter within the pharmaceutical domain. This distribution requires the applicant to monitor different examination styles simultaneously while maintaining a consistent overall strategy for the portfolio.
KNIGHT, TERESA E is the busiest examiner for the company, who is responsible for 1 busiest examiner pending office action. The remaining pending action is assigned to the other distinct examiner. Because the portfolio is split across 2 distinct art units, the prosecution strategy may need to account for varying examination standards and timelines typical of different pharmaceutical classifications. Practitioners should be prepared to address the specific concerns of separate officials, even though the technical focus remains within the biotechnology field. The presence of multiple units indicates that the company's applications are classified under different categories, each with its own set of prior art.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KNIGHT, TERESA E | 1 | 66.1% | +48.1% |
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18425997 | SDC-2 EXOSOME COMPOSITIONS AND METHODS OF ISOLATION AND USE | SPENCE, JENNIFER SUZANNE | 7d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18425997 | SDC-2 EXOSOME COMPOSITIONS AND METHODS OF ISOLATION AND USE | SPENCE, JENNIFER SUZANNE | 7d |
| 18599002 | STROMAL STEM CELLS | KNIGHT, TERESA E | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18599002 | STROMAL STEM CELLS | KNIGHT, TERESA E | 1634 | DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18425997 | SDC-2 EXOSOME COMPOSITIONS AND METHODS OF ISOLATION AND USE | SPENCE, JENNIFER SUZANNE | 1633 | §101§103Other | Non-Final OA | 7d | Pending | Jan 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrbsen Therapeutics Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Teresa E Knight has the most, with 1 of Orbsen Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
